id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-P-0124-0002,FDA,FDA-2001-P-0124,FDA/CDER  to GlaxoSmithKline,Other,PAV-Petition Approval,2002-01-22T05:00:00Z,2002,1,,,2008-04-25T02:25:49Z,,0,0,09000064804dd8f2
FDA-2001-P-0124-0001,FDA,FDA-2001-P-0124,FDA/DDM to GlaxoSmithKline,Other,ACK-Acknowledgement Letter,2001-06-14T04:00:00Z,2001,6,,,2008-04-25T02:25:49Z,,0,0,09000064804dd8dc